Otsuka moved to deepen its neuropsychiatry portfolio through a $700 million upfront acquisition of Transcend Therapeutics (deal value roughly $1.2 billion including milestones). Otsuka plans to take control of TSND-201, an experimental methylone analog designed to rapidly and sustainedly enhance neuroplasticity for PTSD and other psychiatric conditions. The article highlights Transcend’s clinical development path, including mid-stage trial results published in JAMA Psychiatry and ongoing U.S. Phase 3 recruitment. It also frames Otsuka’s rationale around a differentiated profile intended to avoid the key serotonin receptor associated with hallucinogenic effects, a distinction that regulators have weighed in the broader psychedelic-adjacent space. For market watchers, the deal is a direct bet on “neuroplasticity-first” therapeutics and adds scale to Otsuka’s broader pharmaceutical pipeline as large pharma continues to build options in psychiatry beyond classic receptor targets.